ReviewFrontiers in cellular and infection microbiology2024
Progress of research and application of
Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Weizmannia coagulans BC99 improved intestinal motility and chronic constipation through regulating gut microbiota: a randomized, double-blind, placebo-controlled trial.European journal of nutrition · 2026Trial
- Ecological Engineering of the Human Gut Microbiome: A Narrative Review and Framework for Next-Generation Therapeutics.Microorganisms · 2026Review
- Prophylactic Administration of EngineeredMicroorganisms · 2026Article
- Review
- Transcriptional Analysis of Cell Division-Related Genes inMicroorganisms · 2026Article
- Article
- Article
- Bile Salt Tolerance Determines Intestinal Colonization Efficacy ofInternational journal of molecular sciences · 2026Article
- The antibacterial mechanism of the extracellular product derived from Heyndrickxia coagulans against Staphylococcus aureus.Archives of microbiology · 2026Article
- Probiotic Properties In Vitro ofMicroorganisms · 2025Article
- Heyndrickxia coagulans LMG S-24828 Is a Safe Probiotic Strain Capable of Germinating in the Human Gut.Probiotics and antimicrobial proteins · 2025Article
- Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens.Gut microbes · 2025Review
- Improving Nutritional Quality of Peanut Meal through Solid-State Fermentation with Heyndrickxia coagulans.Applied biochemistry and biotechnology · 2025Article
- Iron oxide nanoparticles: biosynthesis, peroxidase-like activity, and biosafety.Applied microbiology and biotechnology · 2025Review
- Oral administration of probiotic spores-based biohybrid system for efficient attenuation of Salmonella Typhimurium-induced colitis.Journal of nanobiotechnology · 2025Article
- Effects ofAnimals : an open access journal from MDPI · 2025Article
- Article
- Clinical and In Vitro Safety ofMicroorganisms · 2024Article
- Article
- Lipoteichoic Acid fromNutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics are defined as living or dead bacteria and their byproducts that maintain the balance of the intestinal microbiome. They are non-toxic, non-pathogenic, and do not release any toxins either within or outside the body. Adequate consumption of probiotics can enhance metabolite production, increase immunity, maintain a balanced intestinal flora, and stimulate growth. Probiotics do not have negative antibiotic effects and help maintain the natural flora in animals in a balanced state or prevent dysbacteriosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.